UroGen Pharma Ltd. (URGN) — Financial statements
Income statement, balance sheet, and cash flow for UroGen Pharma Ltd. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 110↑21.4% | 90↑9.3% | 83↑28.5% | 64↑34.0% | 48 | |
| Cost of Revenue | 12↑40.2% | 9↓5.1% | 9↑22.3% | 8↑48.4% | 5 | |
| Gross Profit | 97↑19.4% | 82↑11.1% | 73↑29.4% | 57↑32.2% | 43 | |
| Operating Expenses | ||||||
| R&D Expenses | 67↑17.4% | 57↑25.3% | 46↓13.8% | 53↑11.0% | 48 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 155 | 0.00↓100.0% | 93↑12.6% | 83 | 0.00 | |
| Other Expenses | 0.00↓100.0% | 121 | 0.00 | 0.00↓100.0% | 88 | |
| Operating Expenses | 222↑24.6% | 178↑28.4% | 139↑2.3% | 136↑0.4% | 135 | |
| Total Costs & Expenses | 235↑25.4% | 187↑26.3% | 148↑3.4% | 143↑2.2% | 140 | |
| Operating Results | ||||||
| Operating Income | -125↓29.0% | -97↓47.7% | -66↑17.1% | -79↑14.4% | -92 | |
| Depreciation & Amortization | 2↑632.8% | 0.33↓80.7% | 2↓6.2% | 2↑118.7% | 0.83 | |
| EBITDA | -136↓42.3% | -95↓58.0% | -60↑20.8% | -76↑16.7% | -91 | |
| EBIT | -138↓44.3% | -96↓54.2% | -62↑20.5% | -78↑15.5% | -92 | |
| Interest & Other Income | ||||||
| Net Interest Income | -28↓670.2% | -4↑70.0% | -12↓61.0% | -8↓2154.8% | 0.37 | |
| Interest Income | 6↓33.0% | 9↑237.0% | 3↑181.6% | 0.94↑157.0% | 0.37 | |
| Interest Expense | 34↑170.3% | 13↓14.9% | 15↑74.4% | 8 | 0.00 | |
| Non-Operating Income | 13↑1300.7% | -1↑68.4% | -3↓244.5% | -1 | 0.00 | |
| Other Income / Expenses | -29↓4.7% | -27↑16.9% | -33↓13.1% | -29↓69.7% | -17 | |
| Income Before Tax | -153↓23.7% | -124↓26.2% | -98↑9.0% | -108↑1.2% | -109 | |
| Income Tax Expense | 0.08↓97.2% | 3↓27.8% | 4↑123.4% | 2↑21.1% | 1 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -153↓21.0% | -127↓24.1% | -102↑6.9% | -110↑0.9% | -111 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -153↓21.0% | -127↓24.1% | -102↑6.9% | -110↑0.9% | -111 | |
| Bottom-Line Net Income | -153↓21.0% | -127↓24.1% | -102↑6.9% | -110↑0.9% | -111 | |
| EPS (Basic) | -3.19↓7.8% | -2.96↑16.6% | -3.55↑25.9% | -4.79↑3.4% | -4.96 | |
| EPS (Diluted) | -3.19↓7.8% | -2.96↑16.6% | -3.55↑25.9% | -4.79↑3.4% | -4.96 | |
| Weighted Average Shares | 48↑12.2% | 43↑48.7% | 29↑26.4% | 23↑2.1% | 22 | |
| Weighted Average Diluted Shares | 48↑12.2% | 43↑48.7% | 29↑26.4% | 23↑2.1% | 22 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.